News Nov. 18, 2020 GNS561’s successful phase 1b trial completed Genoscience Pharma completes successful phase 1b trial evaluating GNS561, PPT-1 inhibitor, in patients with primary…Read More
News July 22, 2020 GNS561, a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-β1 inhibition Marseille, July 22, 2020_ Therapeutic Advances in Chronic disease just published Genoscience Pharma's article E…Read More
News 18 June, 2020 Our COVID-19 research Project supported by the French Government Marseille, June 18, 2020_ The French Government announced in today's press release that Genoscience Pharma…Read More
News April 6, 2020 COVID-19, GNS561’s Assault begins in France ! Marseille, April 6, 2020 — Genoscience Pharma Starts a phase 2 multicenter study using GNS561,…Read More
News January 13, 2020 ISO9001:2015 Certification for our R&D and Clinical Activities in Oncology Marseille, January 13, 2020 - Genoscience Pharma, a clinical-stage biotechnology company dedicated to discovering and…Read More
News December 16, 2019 GNS561 to treat pancreas or colorectal cancer with liver metastasis GENOSCIENCE PHARMA Announces Extension of GNS561 Phase 1/2 Clinical Trial to Patients with Pancreas or…Read More
News November 14, 2019 Outstanding Data on GNS561 in Combination with a PD-1 Inhibitor Outstanding Data on GNS561 in Combination with a PD-1 Inhibitor to Be Presented at the…Read More
News September 25, 2019 Invest in the Future of Health Biotech, European Biotech Week Invest in the Future of Health Biotech during the European Biotech Week 2019 (Brussels) …Read More
News June 3, 2019 S.A.B Meeting in Chicago, during ASCO 2019 Scientific Advisory Board Meeting during ASCO 2019 Chicago, USA, June 3, 2019 — Genoscience…Read More
News April 17, 2019 Chaim Hurvitz, New Board of Directors Member Chaim Hurvitz, New Board of Directors Member Chaim Hurvitz has joined Genoscience Pharma Board…Read More